| Renal medullary carcinoma: Molecular, pathological and clinical evidence for ... - UroToday |
|
|
UroTodayTo present the molecular rationale and potential clinical benefit of topoisomerase II (TopoII)-inhibiting therapy for renal medullary carcinoma (RMC), ... read more |